pilotstudy- efficacy of infectoscab 5% creme in patients with scabies

pilotstudy- efficacy of infectoscab 5% creme in patients with scabies - pilotstudy- efficacy of infectoscab 5% creme in patients with scabies

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2018-004494-27-AT

Enrollment

Registered

2019-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scabies MedDRA version: 20.1 Level: LLT Classification code 10039511 Term: Scabies System Organ Class: 10021881 - Infections and infestations MedDRA version: 20.0 Level: PT Classification code 10063409 Term: Acarodermatitis System Organ Class: 10021881 - Infections and infestations

Interventions

Trade Name: Infectoscab 5% Creme Product Name: Infectoscab 5% Creme Pharmaceutical Form: Cutaneous emulsion INN or Proposed INN: Permethrin CAS Number: 52645-53-1 Current Sponsor code: n.a. Other desc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: light-microscope confirmed scabies - ages =6 years (when parents are treating) Are the trial subjects under 18? yes Number of subjects for this age range: 3 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 44 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 3

Exclusion criteria

Exclusion criteria: Scabies norvegica/crustosa use of Infectoscab 5% creme in the past 4 weeks or multiple application without response in the last 6 months. unse of ivermectin orally in the past 3 months sensitivity/allergy against Infectoscab 5% creme (e.g. Permethrin, Cetylstearylalkohol (Typ A) or Sorbinsäure) pregnancy or breast-feeding woman mental retardation, alcohol abuse or non-compliance

Design outcomes

Primary

Measure	Time frame
Main Objective: Increasing numer of patients with scabies. Decreasing respond to Infectoscab 5% Creme. ;Secondary Objective: not applicable;Primary end point(s): Therapy with Infectoscab 5% Creme (days 0 and 7 whole body) has a failure rate of >30% ;Timepoint(s) of evaluation of this end point: 3-5 weeks	—

Secondary

Measure	Time frame
Secondary end point(s): additional application of Infrectoscab 5% Creme at primary affected regions (e.g. hands, feet, genitals) for 7 consequtive days can lead to a higher curing rate. ;Timepoint(s) of evaluation of this end point: 3-5 weeks	—

Countries

Austria

Contacts

Public ContactUniversitäts-Hautklinik Salzburg

Landeskrankenhaus Salzburg

d.meyersburg@gmx.de+435725558673

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Mar 27, 2026